Biblio
Effect of graft-versus-host disease on outcomes of HLA-haploidentical peripheral blood transplantation using post-transplant cyclophophamide. Bone Marrow Transplant. 2023.
Effects of combined test dose and therapeutic drug monitoring strategy in exposure-directed busulfan. Ann Hematol. 2023.
Epitope mismatch at HLA-DRB1 associates with reduced relapse risk in cord blood transplant for standard-risk hematological malignancy. Transplant Cell Ther. 2023.
Establishment of a Predictive Model for GvHD-free, Relapse-free Survival after Allogeneic HSCT using Ensemble Learning. Blood Adv. 2021.
Hematopoietic stem cell transplantation for diffuse large B-cell lymphoma having 8q24/MYC rearrangement in Japan. Hematol Oncol. 2020.
High dose chemotherapy with autologous stem cell transplantation in primary central nervous system lymphoma: Data from the Japan Society for Hematopoietic Cell Transplantation (JSHCT) registry. Biol Blood Marrow Transplant. 2019.
Impact of donor source on allogeneic hematopoietic stem cell transplantation for mature T- and NK-cell neoplasms in the Kyoto Stem Cell Transplantation Group. Biol Blood Marrow Transplant. 2020.
Low- versus standard-dose post-transplant cyclophosphamide as GVHD prophylaxis for haploidentical transplantation. Br J Haematol. 2023.
Mild Acute Graft-Versus-Host Disease Improves Outcomes After HLA-Haploidentical-Related Donor Transplantation Using Posttransplant Cyclophosphamide and Cord Blood Transplantation. Cell Transplant. 2023;32:9636897231194497.